Advertisement
Collaboration › Details
Medigene–Needham: investor conference, 201803 supply service Medigene presents at Annual Needham Healthcare Conference in NY
Period | 2018-03-27 � 2018-03-28 | |
Region | New York, NY | |
Country | United States (USA) | |
Predecessor | Medigene–Needham: investor conference, 201704 supply service Medigene presents at Annual Needham Healthcare Conference in NY | |
Partner, 1st | Medigene AG (FSE: MDG1, Prime Standard) | |
Group | Medigene (Group) | |
Partner, 2nd | Needham & Company, LLC | |
Group | Needham (Group) | |
Product | Needham & Company 17th Annual Healthcare Conference 2018 New York | |
Product 2 | T cell therapy | |
Person | Taapken, Thomas (InflaRx 202010– CFO before Imcyse + Medigene + Epigenomics + Biotie/elbion + DVC + Burrill) | |
Medigene AG. (2/26/18). "Press Release: Medigene Announces Participation at Four Upcoming Conferences". Planegg.
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming investors, business development and scientific conferences:
Biologics & Biosimilars Congress
Date: 5 - 6 March 2018
Location: Berlin, Germany
Annual ROTH Conference
Date: 11 - 13 March 2018
Location: Orange County, CA, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation for investors on 13 March.
BIO-Europe Spring
Date: 12 - 14 March 2018
Location: Amsterdam, Netherlands
Annual Needham Healthcare Conference
Date: 27 - 28 March 2018
Location: New York, USA
Dr. Thomas Taapken, CFO of Medigene, will hold a company presentation on 28 March.
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com
Record changed: 2018-02-26 |
Advertisement
More documents for Medigene (Group)
- [1] Medigene AG. (11/21/23). "Press Release: Medigene AG Announces Prioritization of Pipeline and Resource Allocation as Well as Extension of Cash Runway". Planegg....
- [2] Medigene AG. (5/3/23). "Press Release: Medigene AG Reports Financial Results and Business Update for Q1 2023". Martinsried....
- [3] Medigene AG. (5/2/23). "Press Release: Medigene Acquires Worldwide, Exclusive License of CD40L-CD28 Costimulatory Switch Receptor". Planegg....
- [4] Medigene AG. (2/1/23). "Press Release: Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications". Planegg....
- [5] Medigene AG. (1/18/23). "Press Release: Medigene Receives $3 Million Milestone Payment from 2seventy bio". Planegg....
- [6] Medigene AG. (2/25/22). "Press Release: Dr. Selwyn Ho Appointed New CEO of Medigene". Lisbon....
- [7] BioNTech SE. (2/21/22). "Press Release: BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer". Mainz & Martinsried....
- [8] Medigene AG. (1/28/21). "Press Release: Focus on Solid Tumors – Discontinuation of MDG1021 Development Program". Planegg-Martinsried....
- [9] Medigene AG. (1/13/21). "Press Release: Medigene Expands Patent Protection of Its Technologies in Key Markets, the USA and Europe". Planegg-Martinsried....
- [10] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top